Bay Area biotech giant Bio-Rad to lay off hundreds after $1.8 billion loss
Bio-Rad Laboratories is slashing 5% of its staff, including over 100 in its Bay Area hometown, amid struggles in the biotech ...
Bio-Rad Laboratories Shares Fall on 4Q Sales Miss, Cost-Cutting Plans
Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...
Bio-Rad's Expanding Profit Margins and Stake in Sartorius Drive Long-Term Value
As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...
Bio-Rad price target lowered to $447 from $477 at RBC Capital
RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company ...
RBC Capital Reaffirms Their Buy Rating on Bio-Rad Laboratories (BIO)
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report), with a ...
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions
Q4 2024 Management View Chief Operating Officer Jon DiVincenzo stated that Bio-Rad met its revised 2024 guidance for revenue and operating margin, achieving gross margin expansion through ...